Aravax secures FDA Fast Track designation for PVX108 peanut allergy immunotherapy

Aravax secured FDA Fast Track designation for PVX108, a novel peanut allergy immunotherapy, enabling accelerated development and rolling review in the US. The Phase II trial is underway with data expected later in 2026, positioning PVX108 ahead of competing programs in clinical progress.

This Wire brief sits within Fusion42's coverage of Biotech. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.